Pelthos Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 9.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 35.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Details
| Name | Pelthos Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 92 |
| Founded | 2002 |
| Ceo | Scott Plesha |
| Country | United States |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1711262048 |
| Cusip | 171126204 |
| Cik | 1919246 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Scott M. Plesha | Chief Executive Officer, President and Director |
| Sai Rangarao M.B.A. | Chief Commercial Officer |
| John M. Gay CPA | Chief Financial Officer, Treasurer and Secretary |
Contact
| Address | 4020 Stirrup Creek Drive, Suite 110, Durham, North Carolina 27703, United States |
| Phone | 919 908 2400 |
| Website | https://pelthos.com |